N/A N=72 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
Lymphatic Filariasis
Primary: Dermatology Life Quality Index (DLQI) Domain Scores — 3; 0; 1; 0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
Lymphatic Filariasis
Primary: Microfilarial Counts at 1 Year — 0; 0; 0 MF/ML — p=<0.2
N/A N=17,108 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Lymphatic Filariasis · Soil Transmitted Helminth Infections
Primary: Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood — 54; 36; 146; 46 Participants
Phase 3 N=164 Moxidectin for LF, Cote d'Ivoire (DOLF)
Lymphatic Filariasis
Primary: Clearance of Microfilaremia (IA vs. MoxA) — 8; 18; 24; 27 Participants
Phase 4 N=50 Lymphedema Study for Arm or Leg Lymphedema
Lymphedema
Primary: Part 1: Count of Participants Able to Complete Ketoprofen Treatment — 50 Participants
Phase 2 N=8 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
Loiasis
Primary: Peak Eosinophil Count Post-treatment — 61; 245.6 percent of baseline eosinophil count — p=0.028
Phase 4 N=12 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
Loiasis
Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68
Phase 3 N=356,912 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Helminthiasis · Filariasis
Primary: Comparison of Arms - Benin — 322; 748; 11; 11 Participants
N/A N=75 Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status
Lymphedema · Breast Cancer
Primary: Number of Participants With Successful Assessment of Lymphedema by Multiple Frequency Bioimpedance Spectroscopy — 19; 21; 22 participants
Phase 2 N=19 Sildenafil for the Treatment of Lymphatic Malformations
Lymphatic Malformations · Lymphatic Diseases
Primary: Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination. — 5.89; -8.54; -0.642 percentage of volume
Phase 4 N=41 Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
Loiasis
Primary: Cross-reactive Antigenemia — 12 Participants
N/A N=18 Imaging Biomarkers of Lymphatic Dysfunction
Secondary Lymphedema
Primary: Assessing a Change in Bioimpedance Spectroscopy (BIS) — 1.3; 1.8 Change of score on a scale
Phase 2 N=82 Acupuncture for Chronic Lymphedema
Breast Cancer With Chronic Lymphedema
Primary: Lymphedema as Measured at Baseline and at 6 Weeks — 4.74; 4.82; 4.29; 4.76 cm
Phase 4 N=74 Post-Operative Drainage Following Lymph Node Dissection
Malignant Melanoma · Carcinoma, Squamous Cell
Primary: Post-operative Wound Drainage. — 892.5; 762.5; 565; 590 ml — p=0.704
N/A N=80 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
Lymph Node Dissection · Lymphoedema · Lymphocoele
Primary: Postoperative Draining Time — 31; 32 days
N/A N=36 Intermittent Pneumatic Compression in Women With Lipo-lymphedema (Lipedema With Swelling)
Lipedema · Lipolymphedema
Primary: Change in Circumferential Measurements Over Time — -0.5; -1.0; -1.3; -2.0 cm
Phase 2 N=7 A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations
Lymphangioma
Primary: Change in Volume of Lymphatic Malformation — 3.7; -4.3; -1.0; -31.7 percentage of volume change
Phase 2 N=54 Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)
Lymphedema
Primary: Change in Skin Thickness of the Calf of the Most Affected Leg, Measured by Skinfold Calipers — -6.83; -7.75 mm
N/A N=194 Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL
Breast Neoplasm · Lymphedema
Primary: Lymphoedema Volume at the Level of the Arm/ Hand — 1.228; 1.249; 1.218; 1.175 Inter-limb ratio
N/A N=13 Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Breast Cancer · Axillary Lymph Node Dissection
Primary: Number and Prevalence of Metastases of Blue Nodes in the ALND Specimen (Nodes Draining the Breast). — 0 participants
Phase 2 N=43 The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination
Yellow Fever
Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer
Phase 2 N=275 OK432 (Picibanil) in the Treatment of Lymphatic Malformations
Lymphatic Malformations
Primary: Number of Participants With Clinical Success at 1 to 6 Months Post-Therapy as Assessed by Imaging — 57 Participants
Phase 3 N=1,673 Efficacy and Safety of IVM/ALB Co-administration
Trichuriasis
Primary: Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured) — 24; 32; 16; 140 Participants
Phase 2 N=10 A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Lymphedema
Primary: Change in Volume Ipsilateral Lymphedema in Arm — -161.0; -372.8 mL — p=0.0658
N/A N=24 Study to Evaluate the Safety and Effectiveness of Dayspring for Lower Extremity Lymphedema
Lymphedema · Lymphedema Lower Extremity · Chronic Venous Insufficiency
Primary: LYMQOL (LYMphedema Quality of Life) ***All Relevant Time Points Used in the Calculation in the Time Frame (e.g., Baseline and 3 Months).*** — .83 units on a scale
Phase 4 N=128 Partnership for Rapid Elimination of Trachoma
Trachoma
Primary: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline — 30.7; 30.3; 31.1; 30.5 community
Phase 3 N=12,979 Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
Onchocerciasis
Primary: Incidence and Severity of Treatment Emergent Adverse Events — 346; 79; 1199; 288 participants
N/A N=32 Fibrin Glue in Inguinal Lymphadenectomy
Seroma
Primary: Number of Participants With Seroma Formation — 2; 8 participants — p=0.022
Phase 4 N=50 Low Level Laser Treatment and Breast Cancer Related Lymphedema
Lymphedema
Primary: LDex Change- — 28.0; 17.8; 22.2 LDex
Phase 2 N=12 Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Microcystic Lymphatic Malformation
Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants